Preview

Артериальная гипертензия

Расширенный поиск

Эссенциальная гипертензия у пациентов с сахарным диабетом 2-го типа: актуальные вопросы антигипертензивной терапии в свете медицины, основанной на доказательствах

Полный текст:

Аннотация

В статье приведены данные мировой литературы, освещающие проблему антигипертензивной терапии у пациентов с сахарным диабетом 2 -готипа преимущественно с точки зрения результатов крупных рандомизированных исследований. В работе обсуждаются возможности традиционных и современных подходов в отношении снижения кровяного давления, обеспечения должной органопротекции и метаболической нейтральности, влияния на прогноз и сохранения высокой приверженности к антигипертензивной терапии у лиц с сахарным диабетом 2-го типа.

Об авторах

А. В. Барсуков
Военно-медицинская академия им. С.М. Кирова, Санкт-Петербург
Россия


М. С. Таланцева
Военно-медицинская академия им. С.М. Кирова, Санкт-Петербург
Россия


Список литературы

1. Treating high blood pressure in diabetes: the evidence // Semin. Vasc. Med. <http://www.ncbi.nlm.nih.gov/pubmed/16222604> - 2002. - Vol. 2, № 2. - P. 127-137.

2.

3. Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance from recent controlled randomized trials? // J. Hypertens. - 2002. - Vol. 20, № 11. - P. 2099-2110.

4.

5. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. - 2009. - Vol. 27, № 11. - P. 2121-2158

6.

7. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus // N. Engl. J. Med. - 2010. - Vol. 362, № 17. - P. 1575-1585

8.

9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type-2 diabetes: UKPDS 38 // Br. Med. J. - 1998. - Vol. 317, № 7160. - P. 703-713

10.

11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39 // Br. Med. J. - 1998. - Vol. 317, № 7160. - P.713-720.

12.

13. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. - 1

14.

15. -Vol. 351, № 9118. - P.1755-1762.

16.

17. Curb J.D., Pressel S.L., Cutler J.A. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease in older diabetic patients with isolated systolic hypertension // J. Am. Med. Assoc. - 1996. - Vol. 276, № 23. - P.1886-1892.

18.

19. Tuomilehto J., Rastenyte D., Birkenhager W.H. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension // N. Engl. J. Med. - 1999. - Vol. 340, № 9. - P. 677-684.

20.

21. Niklason A., Hedner T., Niskanen L., Lanke J. Captopril Prevention Project Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients - a subanalysis of the Captopril Prevention Project (CAPPP) // J. Hypertens. - 2004. - Vol. 22, № 3. - P. 645-652.

22.

23. Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes // N. Engl. J. Med. - 2008. - Vol. 359, № 15. - P. 1565-1576.

24.

25. Lindholm L.H., Hansson L., Ekbom T. et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group // J. Hypertens. - 2000. - Vol. 18, № 11. - Р. 1671-1675

26.

27. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy // Lancet. - 2000. - Vol. 355, № 9200. - P. 253-259.

28.

29. Lindholm L.H., Ibsen H., Dahlof B. et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. - 2002. - Vol. 359, № 9311. - P. 1004-1010.

30.

31. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. - 2002. - Vol. 288, № 23. - P. 2981-2997.

32.

33. Mancia G., Brown M., Castaigne A. et al. INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) // Hypertension. - 2003. - Vol. 41, № 3. - P. 431-436.

34.

35. Dahlof B., Sever P., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial // Lancet. - 2005. - Vol. 366, № 9489. - P. 895-906.

36.

37. Patel A., ADVANCE Collaborative Group, MacMahon S., Chalmers J., Neal B. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial // Lancet. - 2007. - Vol. 370, № 9590. - P. 829-840.

38.

39. Du X., Ninomiya T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ninomiya%20T%22%5BAuthor%5D>., de Galan B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22de%20Galan%20B%22%5BAuthor%5D>. et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study // Eur. Heart. J. - 2009. - Vol. 30, № 9. - P. 1128-1135.

40.

41. Weber M.A., Bakris G.L., Jamerson K. et al. Cardiovascular events during differing hypertension therapies in patients with diabetes // J. Am. Coll. Cardiol. - 2010. - Vol. 56, № 1. - P. 77-85.

42.

43. Bakris G., Sarafidis P.A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sarafidis%20PA%22%5BAuthor%5D>., Weir M.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Weir%20MR%22%5BAuthor%5D>. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial // Lancet. - 2010. - Vol. 375, № 9721. - P. 1173-1181.

44.

45. Lindholm L.H. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis // Lancet. - 2005. - Vol. 366, № 9496. - P. 1545-1553.

46.

47. Mancia G., De Backer G., Dominiczak A. et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007. - Vol. 25, № 6. - P. 1105-1187.

48.

49. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis // Lancet. - 2007. - Vol. 369, № 9557. - P. 201-207.

50.

51. Lam S.K., Owen A. Incident diabetes in clinical trials of antihypertensive drugs // Lancet. - 2007. - Vol. 369, № 9572. - P. 1513-1514.

52.

53. MacDonald M.R., Petrie M.C., Varyani F. et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program // Eur. Heart J. - 2008. - Vol. 29, № 11. - P. 1377-1385.

54.

55. Julius S., Weber M.A., Kjeldsen S.E. et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy // Hypertension. - 2006. - Vol. 48, № 3. - P. 385-391.

56.

57. Lindholm L.H., Persson M., Alanpovic P., Carlberg B <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Carlberg%20B%22%5BAuthor%5D>., Svensson A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Svensson%20A%22%5BAuthor%5D>., Samuelsson O <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Samuelsson%20O%22%5BAuthor%5D>. Metabolic outcome during 1 year in newly detected hypertensives: results in the antihypertensive treatment and lipid profile in the North of Sweden efficacy evaluation (ALPINE-study) // J. Hypertens. - 2003. - Vol. 21, № 8. - P. 1563-1574.

58.

59. Papademetriou V., Farsang C., Elmfeldt D. et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE) // J. Am. Coll. Cardiol. - 2004. - Vol. 44, № 6. - P. 1175-1180.

60.

61. Pfeffer M.A., Swedberg K., Granger C.B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program // Lancet. - 2003. - Vol. 362, № 9386. - P. 759-766.

62.

63. Barnett A.H., Bain S.C., Bouter P. et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy // N. Engl. J. Med. - 2004. - Vol. 351, № 19. - P. 1952-1961.

64.

65. Yusuf S., Diener H.C., Sacco R.L. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. - 2008. - Vol. 359, № 12. - P. 1225-1237.

66.

67. Kurtz T.W., Klein U. Next generation multifunctional angiotensin receptor blockers // Hypertens Res. - 2009. - Vol. 32, № 10. - P. 826-834.

68.

69. Kurtz T.W. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator // Acta Diabetol. - 2005. - Vol. 42, Suppl. 1. - P. S9-S16.

70.

71. Kasanuki H., Hagiwara N., Hosoda S. et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) // Eur. Heart J. - 2009. - Vol. 30, № 10. - P. 1203-1212.

72.

73. Ruggenenti P., Fassi A., Ilieva A.P. et al. for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes // N. Engl. J. Med. - 2004. - Vol. 351, № 19. - P. 1941-1951.

74.

75. Ruggenenti P., Fassi A., Llieva A. et al. Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial // J. Hypertens. - 2011. - Vol. 29, № 2. - P. 207-216.

76.

77. Parving H.H. Lehnert H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Lehnert%20H%22%5BAuthor%5D>.,

78. Brцchner-Mortensen J <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Br%C3%B6chner-Mortensen%20J%22%5BAuthor%5D>.

79. , Gomis R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gomis%20R%22%5BAuthor%5D>.,

80. Andersen S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Andersen%20S%22%5BAuthor%5D>.,

81. Arner P <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Arner%20P%22%5BAuthor%5D>.;

82. Irbesartan in patients with type 2 diabetes and microalbuminuria study group <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Irbesartan%20in%20Patients%20with%20Type%202%20Diabetes%20and%20Microalbuminuria%20Study%20Group%22%5BCorporate%20Author%5D>.

83. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. - 2001. - Vol. 345, № 12. - P. 870-878.

84.

85. Lewis E.J., Hunsicker L.G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hunsicker%20LG%22%5BAuthor%5D>.,

86. Clarke W.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Clarke%20WR%22%5BAuthor%5D>.

87. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. - 2001. - Vol. 345, № 12. - P. 851-860.

88.

89. Brenner B.M., Cooper M.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cooper%20ME%22%5BAuthor%5D>.,

90. de Zeeuw D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22de%20Zeeuw%20D%22%5BAuthor%5D>. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. - 2001. - Vol. 345, № 12. - P. 861-869.

91.

92. Bakris G., Burgess E., Weir M. et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy // Kidney Int. - 2008. - Vol. 74, № 3. - P. 364-369

93.

94. Simons L.A., Ortiz M., Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004-2006 // Med. J. Aust. - 2008. - Vol. 188, № 4. - P. 224-227

95.

96. The ONTARGET Investigators, Yusuf S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yusuf%20S%22%5BAuthor%5D>., Teo K.K., Pogue J <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pogue%20J%22%5BAuthor%5D>. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - Vol. 358, № 15. - P. 1547-1559.

97.


Для цитирования:


Барсуков А.В., Таланцева М.С. Эссенциальная гипертензия у пациентов с сахарным диабетом 2-го типа: актуальные вопросы антигипертензивной терапии в свете медицины, основанной на доказательствах. Артериальная гипертензия. 2011;17(6):518-524.

For citation:


Barsukov A.V., Talantzeva M.S. . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(6):518-524. (In Russ.)

Просмотров: 74


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)